This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Find Strong Buy Stocks with this Filtered Zacks Rank 5 Stock Screener
by Benjamin Rains
Zacks Rank #1 (Strong Buy) stocks outperform the market in good and bad times. Today, we show investors how to add two simple filters to narrow down the number of stocks and try to increase performance...
Top Ranked Momentum Stocks to Buy for November 11th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 11th
Surging Earnings Estimates Signal Upside for FULGENT GENETIC (FLGT) Stock
by Zacks Equity Research
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Fulgent Genetics, Inc. (FLGT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fulgent Genetics, Inc. (FLGT).
FULGENT GENETIC (FLGT) Reports Next Week: What Awaits?
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulgent Genetics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Fulgent Genetics has been struggling lately, but the selling pressure may be coming to an end soon.
FULGENT GENETIC (FLGT) Reports Break-Even Earnings for Q3
by Zacks Equity Research
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 100.00% and 1.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will FULGENT GENETIC (FLGT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
FULGENT GENETIC has been struggling lately, but the selling pressure may be coming to an end soon.
Fulgent Genetics (FLGT) Enters Oversold Territory
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Cyber Attack Fears Grip MedTech: 3 Safe Stocks
by Sweta Jaiswal
In the wake of rising incidences of cyber attacks in the MedTech space, we have zeroed down on some stocks which at present are safe-havens for investors.
Quality Systems Ties Up With CoverMyMeds to Enable ePA
by Zacks Equity Research
Quality Systems' (QSII) new collaboration with CoverMyMeds sees bright market prospects.
FULGENT GENETIC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
FULGENT GENETIC has been struggling lately, but the selling pressure may be coming to an end soon.
Why FULGENT GENETICS (FLGT) Could Be Positioned for a Slump
by Zacks Equity Research
FULGENT GENETICS (FLGT) is one stock you should avoid as it has seen significant price decline and negative earnings estimate revisions.